151 related articles for article (PubMed ID: 24143191)
21. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
22. Ki-67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: A consecutive cohort study.
Zhang Y; Zhou Y; Mao F; Yao R; Sun Q
Cancer Commun (Lond); 2020 Apr; 40(4):181-193. PubMed ID: 32291973
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N
Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989
[TBL] [Abstract][Full Text] [Related]
24. Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling.
Vissio E; Metovic J; Osella-Abate S; Bertero L; Migliaretti G; Borella F; Benedetto C; Sapino A; Cassoni P; Castellano I
Br J Cancer; 2020 Feb; 122(3):382-387. PubMed ID: 31780778
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation.
Carbognin L; Sperduti I; Fabi A; Dieci MV; Kadrija D; Griguolo G; Pilotto S; Guarneri V; Zampiva I; Brunelli M; Orvieto E; Nortilli R; Fiorio E; Parolin V; Manfrin E; Caliò A; Nisticò C; Pellini F; Scarpa A; Pollini GP; Conte P; Tortora G; Bria E
Breast; 2017 Oct; 35():21-26. PubMed ID: 28628772
[TBL] [Abstract][Full Text] [Related]
27. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
Jerjees DA; Alabdullah M; Green AR; Alshareeda A; Macmillan RD; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2014 Jun; 145(2):317-30. PubMed ID: 24744091
[TBL] [Abstract][Full Text] [Related]
28. ESPL1 is a candidate oncogene of luminal B breast cancers.
Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
[TBL] [Abstract][Full Text] [Related]
29. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; van de Vijver MJ
Eur J Surg Oncol; 1999 Aug; 25(4):356-63. PubMed ID: 10419704
[TBL] [Abstract][Full Text] [Related]
30. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study.
Healey MA; Hirko KA; Beck AH; Collins LC; Schnitt SJ; Eliassen AH; Holmes MD; Tamimi RM; Hazra A
Breast Cancer Res Treat; 2017 Nov; 166(2):613-622. PubMed ID: 28791482
[TBL] [Abstract][Full Text] [Related]
31. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
[TBL] [Abstract][Full Text] [Related]
32. Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy.
Synnestvedt M; Borgen E; Russnes HG; Kumar NT; Schlichting E; Giercksky KE; Kåresen R; Nesland JM; Naume B
Acta Oncol; 2013 Jan; 52(1):91-101. PubMed ID: 22934555
[TBL] [Abstract][Full Text] [Related]
33. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.
Caly M; Genin P; Ghuzlan A A; Elie C; Fréneaux P; Klijanienko J; Rosty C; Sigal-Zafrani B; Vincent-Salomon A; Douggaz A; Zidane M; Sastre-Garau X
Anticancer Res; 2004; 24(5B):3283-8. PubMed ID: 15510624
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the Ki67 labeling index: a Japanese validation ring study.
Niikura N; Sakatani T; Arima N; Ohi Y; Honma N; Kanomata N; Yoshida K; Kadoya T; Tamaki K; Kumaki N; Iwamoto T; Sugie T; Moriya T
Breast Cancer; 2016 Jan; 23(1):92-100. PubMed ID: 24794952
[TBL] [Abstract][Full Text] [Related]
35. Effect of Ki-67 Expression Levels and Histological Grade on Breast Cancer Early Relapse in Patients with Different Immunohistochemical-based Subtypes.
Liang Q; Ma D; Gao RF; Yu KD
Sci Rep; 2020 May; 10(1):7648. PubMed ID: 32376868
[TBL] [Abstract][Full Text] [Related]
36. PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes.
Lattanzio R; Iezzi M; Sala G; Tinari N; Falasca M; Alberti S; Buglioni S; Mottolese M; Perracchio L; Natali PG; Piantelli M
BMC Cancer; 2019 Jul; 19(1):747. PubMed ID: 31362705
[TBL] [Abstract][Full Text] [Related]
37. Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma.
Arihiro K; Oda M; Ohara M; Kadoya T; Osaki A; Nishisaka T; Shiroma N; Kobayashi Y
Jpn J Clin Oncol; 2016 Dec; 46(12):1081-1087. PubMed ID: 27511992
[TBL] [Abstract][Full Text] [Related]
38. Effect of Ki-67 on Immunohistochemical Classification of Luminal A to Luminal B Subtypes of Breast Carcinoma.
Cirqueira MB; Moreira MA; Soares LR; Cysneiros MA; Vilela MH; Freitas-Junior R
Breast J; 2015; 21(5):465-72. PubMed ID: 26138552
[TBL] [Abstract][Full Text] [Related]
39. The potential utility of geminin as a predictive biomarker in breast cancer.
Sundara Rajan S; Hanby AM; Horgan K; Thygesen HH; Speirs V
Breast Cancer Res Treat; 2014 Jan; 143(1):91-8. PubMed ID: 24292956
[TBL] [Abstract][Full Text] [Related]
40. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS
Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
